[{"address1": "350 Technology Drive", "address2": "Suite 421", "city": "Pittsburgh", "state": "PA", "zip": "15219", "country": "United States", "phone": "412 763 3350", "website": "https://www.neubasetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Mr. Todd P. Branning", "age": 52, "title": "Interim CEO, CFO & Secretary", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 427445, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dietrich A. Stephan Ph.D.", "age": 53, "title": "Founder, President & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 836580, "exercisedValue": 0, "unexercisedValue": 992502}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.9891, "open": 0.4454, "dayLow": 0.43, "dayHigh": 0.54, "regularMarketPreviousClose": 0.9891, "regularMarketOpen": 0.4454, "regularMarketDayLow": 0.43, "regularMarketDayHigh": 0.54, "beta": 1.013, "forwardPE": -0.042000003, "volume": 1361174, "regularMarketVolume": 1361174, "averageVolume": 233444, "averageVolume10days": 304028, "averageDailyVolume10Day": 304028, "bid": 0.4302, "ask": 0.5198, "bidSize": 100, "askSize": 100, "marketCap": 1785545, "fiftyTwoWeekLow": 0.43, "fiftyTwoWeekHigh": 5.4, "fiftyDayAverage": 0.780784, "twoHundredDayAverage": 0.9661028, "currency": "USD", "enterpriseValue": -5449650, "floatShares": 3298520, "sharesOutstanding": 3729210, "sharesShort": 199815, "sharesShortPriorMonth": 12641, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.053600002, "heldPercentInsiders": 0.13437, "heldPercentInstitutions": 0.12768, "shortRatio": 0.54, "shortPercentOfFloat": 0.0552, "impliedSharesOutstanding": 3729210, "bookValue": 2.45, "priceToBook": 0.19542857, "lastFiscalYearEnd": 1664496000, "nextFiscalYearEnd": 1696032000, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -24585756, "trailingEps": -18.6, "forwardEps": -11.4, "lastSplitFactor": "1:20", "lastSplitDate": 1686787200, "enterpriseToEbitda": 0.233, "52WeekChange": -0.8665184, "SandP52WeekChange": 0.29191303, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NBSE", "underlyingSymbol": "NBSE", "shortName": "NeuBase Therapeutics, Inc.", "longName": "NeuBase Therapeutics, Inc.", "firstTradeDateEpochUtc": 1085751000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "dd3cf6cf-f9cd-3b1e-9591-aeb04f3b643b", "messageBoardId": "finmb_596992951", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4788, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 12570359, "totalCashPerShare": 3.371, "ebitda": -23408468, "totalDebt": 5335165, "quickRatio": 7.211, "currentRatio": 7.403, "debtToEquity": 58.393, "returnOnAssets": -0.43032002, "returnOnEquity": -0.93461996, "freeCashflow": -15184278, "operatingCashflow": -24686866, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-27"}]